After a disappointing phase 1 showing, Janux Therapeutics is kicking one of its bispecific T-cell engagers (TCEs) ...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the ...
Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...
Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the ...
The U.S. Food and Drug Administration has broadened approval of Teplizumab-developed by Sanofi-to include children as young ...
BOSTON, April 01, 2026 (GLOBE NEWSWIRE)-- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company's lead candidate, intranasal foralumab, for Long COVID associated "brain fog".BOSTON, ...
USC researchers are developing a computational model that combines satellite data and physics-based simulations to forecast a ...
3don MSN
Redistricting reshapes the battlefield as Maloy and Lyman spar over how to rebuild trust in Congress
Rep. Celeste Maloy is defending her short tenure as Phil Lyman brings his focus on transparency to a federal race.
OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...
U.S. House Rep. Jeff Hurd (R-Grand Junction) will face familiar competition in this summer’s 3rd Congressional District ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results